Cardiology Medical News about Cholesterol Esters

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
European Heart Journal, 10/22/09

Chapman MJ et al. – This review appraises recent evidence for a central role of CETP in the action of current lipid–modulating agents with HDL–raising potential, i.e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacological agents under development which directly inhibit CETP. New CETP inhibitors, such as dalcetrapib and anacetrapib, are targeted to normalize HDL/apoA–I levels and anti–atherogenic activities of HDL particles. Further studies of these CETP inhibitors, in particular in long–term, large–scale outcome trials, will provide essential information on their safety and efficacy in reducing residual cardiovascular risk.

<< Previous
In and Out-of-hospital cardiac arrest and echography: A review

Next >>
Early warning signs of an acute myocardial infarction and their...